What is Small Pharma?
Small Pharma Inc. is a London-based biotechnology company dedicated to pioneering novel treatments for mental health disorders through the development of short-acting psychedelic compounds. The company's core focus lies in creating innovative therapies that address unmet needs in psychiatric care. Its lead investigational drug, SPL026, is undergoing clinical evaluation for its efficacy in treating depressive disorder. Beyond this, Small Pharma is actively engaged in preclinical research for other promising tryptamine analogues, SPL028 and SPL029, as well as an oral formulation of 6-hydroxynorketamine, designated SPL801, further underscoring its commitment to a diversified and robust drug development pipeline.
How much funding has Small Pharma raised?
Small Pharma has raised a total of $1.8M across 3 funding rounds:
Multiple Rounds
$1.8M
Private Equity (2017): $1M with participation from Angel CoFund
Grant (2017): $174K led by Angel CoFund
Other Financing Round (2017): $584K supported by Innovate UK
Key Investors in Small Pharma
Angel CoFund
Angel CoFund is a UK-based investment fund that supports promising businesses through angel and co-investment, collaborating with sector-focused angel investors to enhance the investment process and drive capital growth.
Innovate UK
Innovate UK is an innovation agency that provides funding and support for businesses to drive innovation and technological advancement within the UK.
What's next for Small Pharma?
With the recent major strategic investment and substantial overall backing, Small Pharma is poised to accelerate its clinical development programs and potentially expand its research into new therapeutic areas. The company's focus on short-acting psychedelics positions it at the forefront of a rapidly evolving field in psychiatric medicine. Future endeavors will likely involve advancing SPL026 through further clinical trials, potentially leading to regulatory submissions, and progressing its preclinical candidates towards human studies. This strategic financing will be crucial for scaling operations, attracting top talent, and navigating the complex regulatory landscape inherent in pharmaceutical development.
See full Small Pharma company page
